Advertisement
Canada markets open in 54 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7325
    +0.0002 (+0.03%)
     

  • CRUDE OIL

    84.16
    +0.59 (+0.71%)
     

  • Bitcoin CAD

    87,873.08
    +751.04 (+0.86%)
     

  • CMC Crypto 200

    1,388.43
    -8.11 (-0.58%)
     

  • GOLD FUTURES

    2,355.90
    +13.40 (+0.57%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.6860
    -0.0200 (-0.42%)
     

  • NASDAQ futures

    17,727.25
    +159.75 (+0.91%)
     

  • VOLATILITY

    15.64
    +0.27 (+1.76%)
     

  • FTSE

    8,115.11
    +36.25 (+0.45%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6826
    +0.0005 (+0.07%)
     
MARKETS LIVE BLOG:

STOCK FUTURES JUMP, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Today's Research Reports on Microbix Biosystems, Hemostemix, DiaMedica Therapeutics and Nuvo Pharmaceuticals

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / November 21, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://marketedgereport.com and get exclusive access to our numerous research reports and market updates.

The Market Edge Initiates Coverage on:

Microbix Biosystems Inc.
https://marketedgereport.com/report/MBX.TO/

Hemostemix Inc.
https://marketedgereport.com/report/HEM.V/

DiaMedica Therapeutics Inc.
https://marketedgereport.com/report/DMA.V/

Nuvo Pharmaceuticals Inc.
https://marketedgereport.com/report/NRI.TO/

ADVERTISEMENT

Microbix Biosystems’ stocks had no change Tuesday, to close the day at $0.20. The stock recorded a trading volume of 57,000 shares, which was above its three months average volume of 57,780shares. In the last year, Microbix Biosystems' shares have traded in a range of 0.18 - 0.34. The share price has gained 11.11% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.21 is lower than its 200-day moving average of $0.26. Shares of Microbix Biosystems have fallen approximately 35.48 percent year-to-date.

Access The Market Edge's Microbix Biosystems Inc. Research Report:
https://marketedgereport.com/report/MBX.TO/

On Tuesday, shares of Hemostemix recorded a trading volume of 61,475 shares, which was below the three months average volume of 216,045 shares. The stock ended the day 18.52% lower at $0.11. The share price has fallen 21.43% from its 52 week high with a 52 week trading range of 0.05 - 0.14. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.11 is greater than its 200-day moving average of $0.08. Shares of Hemostemix have gained approximately 57.14 percent year-to-date.

Access The Market Edge's Hemostemix Inc. Research Report:
https://marketedgereport.com/report/HEM.V/

DiaMedica Therapeutics’ stock moved 8.64% lower Tuesday, to close the day at $5.71. The stock recorded a trading volume of 15,475 shares, which was above its three months average volume of 7,409 shares. In the last year, DiaMedica Therapeutics' shares have traded in a range of 4.20 - 18.00. The share price has gained 35.95% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $9.42 is lower than its 200-day moving average of $11.19. Shares of DiaMedica Therapeutics have fallen approximately 1.55 percent year-to-date.

Access The Market Edge's DiaMedica Therapeutics Inc. Research Report:
https://marketedgereport.com/report/DMA.V/

On Tuesday, shares of Nuvo Pharmaceuticals recorded a trading volume of 100 shares, which was below the three months average volume of 5,834 shares. The stock ended the day 1.46% lower at $2.70. The share price has fallen 34.62% from its 52 week high with a 52 week trading range of 2.55 - 4.13. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.74 is lower than its 200-day moving average of $2.80. Shares of Nuvo Pharmaceuticals have fallen approximately 27.03 percent year-to-date.

Access The Market Edge's Nuvo Pharmaceuticals Inc. Research Report:
https://marketedgereport.com/report/NRI.TO/

Our Actionable Research on Microbix Biosystems Inc. (TSX :MBX.TO), Hemostemix Inc. (TSXV :HEM.V), DiaMedica Therapeutics Inc. (TSXV :DMA.V) and Nuvo Pharmaceuticals Inc. (TSX :NRI.TO) can be downloaded free of charge at The Market Edge.

The Market Edge

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: MarketEdgeReport